Inhibrx Inc (INBX)

11.35 -0.64 (-5.34%) USD  |  NASDAQ  |  Jun 30, 11:57
More

Inhibrx News

News

Headline
Wire
Time (ET)
Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance
PR Newswire
06/30 09:00
Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting
Yahoo
05/19 16:05
Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder
Yahoo
05/16 12:32
Inhibrx's Phase 1 Trial of INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency
MT Newswires
05/16 10:28
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing
PR Newswire
05/16 09:00
Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates
Yahoo
05/09 18:35
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
Yahoo
05/09 17:25
-- Earnings Flash (INBX) INHIBRX Posts Q1 Revenue $929,000
MT Newswires
05/09 16:10
Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
PR Newswire
05/09 16:05
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates
Yahoo
05/05 17:15
The 17% return this week takes Inhibrx's (NASDAQ:INBX) shareholders one-year gains to 25%
Yahoo
05/05 06:18
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
Yahoo
05/03 06:32
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
PR Newswire
04/25 09:00
Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting
PR Newswire
04/05 16:30
Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting
PR Newswire
03/24 16:05
Inhibrx initiated as outperform at SMBC Nikko; sees 98% upside
SA Breaking News
03/16 13:56
SMBC Nikko Starts Inhibrx at Outperform With $40 Price Target
MT Newswires
03/16 04:50
Inhibrx's INBRX-101 for AAT deficiency gets FDA's orphan drug designation
SA Breaking News
03/03 09:45
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
PR Newswire
03/03 09:15
--JMP Securities Adjusts Inhibrx Price Target to $40 From $53, Maintains Market Outperform Rating
MT Newswires
03/02 11:35
Inhibrx Q4 Net Loss Widens; Revenue Ticks Up
MT Newswires
03/01 05:52
Inhibrx GAAP EPS of -$0.55 beats by $0.02, revenue of $2.86M beats by $1.15M
SA Breaking News
02/28 17:39
-- Earnings Flash (INBX) INHIBRX Posts Q4 Loss $-0.55
MT Newswires
02/28 16:21
-- Earnings Flash (INBX) INHIBRX Posts Q4 Revenue $2.86M
MT Newswires
02/28 16:17
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights
PR Newswire
02/28 16:05
Sector Update: Health Care Stocks Still Trying to Overcome Midday Slide
MT Newswires
01/25 15:48
Inhibrx Chief Medical Officer Resigns -- Stocks Drop Amid Elevated Trading Volume
MT Newswires
01/25 14:10
Inhibrx falls after announcing resignation of medical chief
SA Breaking News
01/25 10:09
Inhibrx Shares Initial Dose Escalation Results of INBRX-106 With Keytruda to Treat Tumors
MT Newswires
01/04 16:50
Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data
PR Newswire
01/04 16:05
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
PR Newswire
12/01 16:05
--Credit Suisse Raises Inhibrx's PT to $53 from $44 After Chat with CEO, Notes Higher-than-Consensus Q3 Revenue; Keeps Outperform Rating
MT Newswires
11/10 11:04
-- Earnings Flash (INBX) INHIBRX Posts Q3 Revenue $2.51M
MT Newswires
11/09 16:26
Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
PR Newswire
11/09 16:05
Inhibrx Announces Presentations at SITC 2021
PR Newswire
11/03 08:00
--JMP Securities Adjusts Price Target on Inhibrx to $53 From $46, Maintains Market Outperform Rating
MT Newswires
11/02 06:45
Inhibrx Says INBRX-101 Preliminary Results Showed 'Favorable Safety Profile' in Alpha-1 Antitrypsin Deficiency Patients
MT Newswires
10/12 09:59
Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency
PR Newswire
10/11 16:05
--JMP Securities Starts Inhibrx at Market Outperform with $46 Price Target
MT Newswires
09/21 08:43
Inhibrx Announces Participation in Upcoming Investor Conference
PR Newswire
09/13 16:30
-- Earnings Flash (INBX) INHIBRX Reports Q2 Revenue $954,000
MT Newswires
08/09 16:40
Inhibrx Reports Second Quarter 2021 Financial Results
PR Newswire
08/09 16:38
Inhibrx Kicks Off Mid-Stage Trial in Conventional Bone Cancer Patients, Provides Preliminary Results From Phase 1 Study
MT Newswires
06/21 16:21
Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford
PR Newswire
06/21 16:05
Vertex Won't Move VX-864 into Late-Stage Testing After Disappointing Study Results
MT Newswires
06/11 10:40
Inhibrx Announces Participation in Upcoming Investor Conferences
PR Newswire
05/17 16:05
-- Earnings Flash (INBX) INHIBRX Reports Q1 Loss $-0.51
MT Newswires
05/13 16:13
-- Earnings Flash (INBX) INHIBRX Reports Q1 Revenue $889,000
MT Newswires
05/13 16:13
Inhibrx Reports First Quarter 2021 Financial Results
PR Newswire
05/13 16:10
SEEL, AEZS, SJR and TRCH among midday movers
SA Breaking News
03/15 12:39
Inhibrx EPS beats by $0.14, beats on revenue
SA Breaking News
03/12 09:45
Inhibrx Q4 Loss Narrows as Revenue Improves
MT Newswires
03/12 09:33
-- Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $2.8M
MT Newswires
03/12 09:06
Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist
PR Newswire
03/12 09:00
SOS, WPG, CAN and BLUE among midday movers
SA Breaking News
02/16 12:37
Diffusion Pharmaceuticals, Strongbridge Biopharma leads healthcare gainers; bluebird bio, Cortexyme among major losers
SA Breaking News
02/16 10:58
Seeking Alpha Catalyst Watch
SA Breaking News
02/12 15:15
Analyst Actions: Credit Suisse Adjusts Inhibrx' Price Target to $44 from$28, Keeps Outperform Rating
MT Newswires
02/03 10:42
Inhibrx Announces Participation in Upcoming Investor Conference
PR Newswire
02/01 17:42
FDA Grants Fast Track Status to Inhibrx's Chondrosarcoma Drug
MT Newswires
01/13 10:51
Inhibrx's INBRX-109 wins FDA's Fast Track status
SA Breaking News
01/13 09:25
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
PR Newswire
01/13 09:00
Inhibrx Reports Anti-Tumor Activity From INBRX-106 in First Part of Phase I Study
MT Newswires
01/05 14:42
Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors
SA Breaking News
01/05 12:39
--Analyst Actions: Jefferies Adjusts Inhibrx PT to $50 From $30, Maintains Buy Rating
MT Newswires
12/21 12:29
Sutro Biopharma, Merrimack Pharmaceuticals leads healthcare gainers; Precision BioSciences, Cortexyme among major losers
SA Breaking News
12/04 11:07
Inhibrx Q3 Loss Narrows, Revenue Increases
MT Newswires
11/13 16:18
-- Earnings Flash (INBX) INHIBRX Posts Q3 Revenue $5.9M
MT Newswires
11/13 16:17
Inhibrx EPS misses by $0.07
SA Breaking News
11/13 16:16
Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford
PR Newswire
11/13 16:10
--Analyst Actions: Credit Suisse Adjusts Inhibrx' Price Target to $28 from $26, Keeps Outperform Rating
MT Newswires
11/12 11:08
Inhibrx Observes 92% Disease Control in Updated Interim Results From Chondrosarcoma Trial; Plans FDA Meeting 'Near Future'
MT Newswires
11/11 16:58
Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences
PR Newswire
11/05 16:05
--Analyst Actions: Jefferies Starts Inhibrx at Buy With $30 Price Target
MT Newswires
09/14 09:29
--Analyst Actions: Evercore ISI Starts Inhibrx at Outperform With $30 Price Target
MT Newswires
09/14 06:41
--Analyst Actions: Credit Suisse Starts Inhibrx at Outperform With $26 Price Target
MT Newswires
09/14 06:40
Oxford Finance Discloses $10 Million Credit Facility for Inhibrx
MT Newswires
08/25 13:57
Oxford Finance announces $10M credit facility with Inhibrx
SA Breaking News
08/25 12:33
Oxford Finance Announces $10 Million Credit Facility with Inhibrx, Inc.
PR Newswire
08/25 12:17
Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire
08/21 16:00
Inhibrx gives back some of its IPO pop, -8%
SA Breaking News
08/20 10:56
Inhibrx Prices IPO at $17/Share
MT Newswires
08/19 04:53
Inhibrx prices IPO at $17
SA Breaking News
08/19 03:09